| Biomarker ID | 1588 |
| PMID | 25307116 |
| Year | 2014 |
| Biomarker | XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y; |
| Biomarker Basis | Expression Based |
| Biomolecule | LncRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold); |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Adjacent Normal |
| Type of Biomarker | Diagnostic |
| Cohort | 10 prostate cancer and adjacent normal tissue were chosen for chosen for discovery and 18 similar paired tissues were selected for validation |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Discovery: Microarrays; Validation: qPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |